Vor Biopharma Inc. (VOR)
Vor Biopharma Statistics
Share Statistics
Vor Biopharma has 124.85M shares outstanding. The number of shares has increased by 82.91% in one year.
| Shares Outstanding | 124.85M |
| Shares Change (YoY) | 82.91% |
| Shares Change (QoQ) | 81.8% |
| Owned by Institutions (%) | 89% |
| Shares Floating | 76.79M |
| Failed to Deliver (FTD) Shares | 33.62K |
| FTD / Avg. Volume | 6.81% |
Short Selling Information
The latest short interest is 1.71M, so 2.48% of the outstanding shares have been sold short.
| Short Interest | 1.71M |
| Short % of Shares Out | 2.48% |
| Short % of Float | 4.03% |
| Short Ratio (days to cover) | 2.99 |
Valuation Ratios
The PE ratio is -0.65 and the forward PE ratio is -1.21. Vor Biopharma's PEG ratio is 0.23.
| PE Ratio | -0.65 |
| Forward PE | -1.21 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 0.79 |
| P/FCF Ratio | -0.76 |
| PEG Ratio | 0.23 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Vor Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.19, with a Debt / Equity ratio of 0.33.
| Current Ratio | 5.19 |
| Quick Ratio | 5.19 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | -0.26 |
| Debt / FCF | -0.32 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-735.31K |
| Employee Count | 159 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -69.52% in the last 52 weeks. The beta is -0.41, so Vor Biopharma's price volatility has been lower than the market average.
| Beta | -0.41 |
| 52-Week Price Change | -69.52% |
| 50-Day Moving Average | 1.12 |
| 200-Day Moving Average | 0.98 |
| Relative Strength Index (RSI) | 25.79 |
| Average Volume (20 Days) | 493.51K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -121.19M |
| Net Income | -116.91M |
| EBITDA | -121.19M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.7 |
Balance Sheet
The company has 81.95M in cash and 31.83M in debt, giving a net cash position of 50.12M.
| Cash & Cash Equivalents | 81.95M |
| Total Debt | 31.83M |
| Net Cash | 50.12M |
| Retained Earnings | -456.99M |
| Total Assets | 142.89M |
| Working Capital | 77.89M |
Cash Flow
In the last 12 months, operating cash flow was -99.66M and capital expenditures -229K, giving a free cash flow of -99.89M.
| Operating Cash Flow | -99.66M |
| Capital Expenditures | -229K |
| Free Cash Flow | -99.89M |
| FCF Per Share | -1.45 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VOR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for VOR is $11, which is 1618.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 1618.8% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -5.48 |
| Piotroski F-Score | 2 |